Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer

Currently, fine-needle aspiration is the most frequently used pre-operative technique for diagnosis of malignant thyroid tumors, however, pathologists are unable to reach efficient and accurate differential diagnoses between benign and malignant thyroid nodules. To aid in resolving this issue, immunohistochemistry for galectins (gal)-1, −3, −7, −8, cytokeratin 19 (CK19), Hector Battifora Mesothelial Epitope-1 (HBME-1) and thyroid peroxidase (TPO) was performed on two tissue microarrays composed of 66 follicular adenomas (FA) and 66 papillary carcinomas (PC). The identification of optimal cut-off levels and the diagnostic value of single immunomarkers or combinations were evaluated using the receiver operating characteristic curve analysis. Signal intensities for gal-1, gal-3, CK19 and HBME-1 were significantly greater in PC compared with FA (P<0.001). Conversely, expression levels of TPO were significantly increased in FA compared with PC (P<0.001). Gal-3 and CK19 appeared to be the most sensitive markers (97 and 98%, respectively), whereas galectin-1 was the most specific (97%). The combination of gal-3, CK19 and HBME-1 acted as the most efficient and informative marker panel reaching the greatest specificity (97%) and sensitivity (95%) for the diagnosis of PCs. The findings suggest that this combination of markers may improve the reliability of diagnosis of thyroid cancer.

[1]  Reinhard Windhager,et al.  Galectin-3 Induces a Pro-degradative/inflammatory Gene Signature in Human Chondrocytes, Teaming Up with Galectin-1 in Osteoarthritis Pathogenesis , 2016, Scientific Reports.

[2]  J. Jiménez-Barbero,et al.  Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR. , 2016, Glycobiology.

[3]  A. Shivarudrappa,et al.  Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. , 2015, Journal of clinical and diagnostic research : JCDR.

[4]  I. Soldatovic,et al.  Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature , 2015, Diagnostic Pathology.

[5]  B. Zhang,et al.  Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. , 2015, International journal of clinical and experimental medicine.

[6]  J. Kopitz,et al.  Human chimera-type galectin-3: defining the critical tail length for high-affinity glycoprotein/cell surface binding and functional competition with galectin-1 in neuroblastoma cell growth regulation. , 2014, Biochimie.

[7]  Hui Guo,et al.  Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. , 2014, International journal of clinical and experimental medicine.

[8]  K. Kayser,et al.  Human osteoarthritic knee cartilage: fingerprinting of adhesion/growth-regulatory galectins in vitro and in situ indicates differential upregulation in severe degeneration , 2014, Histochemistry and Cell Biology.

[9]  Robert A. Smith,et al.  The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. , 2014, Experimental and molecular pathology.

[10]  J. Kopitz,et al.  Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target , 2013, Expert opinion on therapeutic targets.

[11]  C. Maenhaut,et al.  Thyroid cancer cell lines: an overview , 2012, Front. Endocrin..

[12]  L. L. de Matos,et al.  Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis , 2012, Diagnostic Pathology.

[13]  F. Kabukçuoğlu,et al.  Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[14]  Christian Fischer,et al.  Tumor suppressor p16INK4a: Downregulation of galectin‐3, an endogenous competitor of the pro‐anoikis effector galectin‐1, in a pancreatic carcinoma model , 2010, The FEBS journal.

[15]  C. Cohen,et al.  Paired box gene 8, HBME‐1, and cytokeratin 19 expression in preoperative fine‐needle aspiration of papillary thyroid carcinoma , 2010, Cancer cytopathology.

[16]  Xiong-zeng Zhu,et al.  Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma , 2010, Journal of Clinical Pathology.

[17]  A. Raz,et al.  Galectins as Cancer Biomarkers , 2010, Cancers.

[18]  A. Bartolazzi,et al.  Galectin-3 detection on large-needle aspiration biopsy improves preoperative selection of thyroid nodules: A prospective cohort study , 2010, Annals of medicine.

[19]  D. Demydenko,et al.  Expression of galectin-1 in malignant tumors. , 2009, Experimental oncology.

[20]  F. Pattou,et al.  Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. , 2008, Thyroid : official journal of the American Thyroid Association.

[21]  A. Krześlak,et al.  Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis. , 2008, Molecular medicine reports.

[22]  J. Kievit,et al.  Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. , 2008, European journal of endocrinology.

[23]  Stephanie L. Lee,et al.  Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[24]  F. Pattou,et al.  A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid , 2008, Virchows Archiv.

[25]  F. Sebag,et al.  Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV , 2008, British Journal of Cancer.

[26]  P. Alken,et al.  Gene‐expression signature of adhesion/growth‐regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance , 2007, Histopathology.

[27]  H. Gharib,et al.  Thyroid nodules: clinical importance, assessment, and treatment. , 2007, Endocrinology and metabolism clinics of North America.

[28]  S. Kwak,et al.  Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the Differential Diagnosis of Thyroid Nodules , 2007, Journal of Korean medical science.

[29]  S. Filetti,et al.  Functional characterization of human thyroid tissue with immunohistochemistry. , 2007, Thyroid : official journal of the American Thyroid Association.

[30]  David D. Roberts,et al.  Proteomic Identification of New Biomarkers and Application in Thyroid Cytology , 2006, Acta Cytologica.

[31]  A. Bartolazzi,et al.  Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms , 2006, Histopathology.

[32]  K. Metze,et al.  Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy , 2005, Histopathology.

[33]  L. Mills,et al.  Galectin‐3 is not useful in thyroid FNA , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[34]  A. Scaloni,et al.  A differential proteomic approach to identify proteins associated with thyroid cell transformation. , 2005, Journal of molecular endocrinology.

[35]  L. Hegedüs,et al.  Thyroid ultrasonography as a screening tool for thyroid disease. , 2004, Thyroid : official journal of the American Thyroid Association.

[36]  K. Shroyer,et al.  The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. , 2004, American journal of clinical pathology.

[37]  Isabelle Camby,et al.  Galectins and cancer. , 2002, Biochimica et biophysica acta.

[38]  M. Niedziela,et al.  Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. , 2002, The Journal of clinical endocrinology and metabolism.

[39]  R. Kiss,et al.  Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. , 2001, Histology and histopathology.

[40]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[41]  C. Cheung,et al.  Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.

[42]  F. Galateau-Sallé,et al.  [HBME-1 immunostaining in thyroid pathology]. , 2001, Annales de pathologie.

[43]  J. Rosai,et al.  Guest Editorial: Two Proposals Regarding the Terminology of Thyroid Tumors , 2000, International journal of surgical pathology.

[44]  M. P. Martegani,et al.  Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Yoshii,et al.  Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.

[46]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.

[47]  A. Fusco,et al.  Expression of galectin‐1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors , 1995, International journal of cancer.

[48]  P. Carayon,et al.  Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues , 1991, Cancer.

[49]  Hans-Joachim Gabius,et al.  Galectins: their network and roles in immunity/tumor growth control , 2016, Histochemistry and Cell Biology.

[50]  B. Zhang,et al.  Significance of CK 19 , TPO , and HBME-1 expression for diagnosis of papillary thyroid carcinoma , 2015 .

[51]  Z. Baloch,et al.  Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: An immunohistochemical tissue microarray analysis , 2006, Endocrine pathology.

[52]  H. Nagaraja,et al.  Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.

[53]  H. Gabius,et al.  Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts , 2001, Cell and Tissue Research.

[54]  Xiong-zeng Zhu,et al.  Diagnostic significance of CK 19 , RET , galectin-3 and HBME-1 expression for papillary thyroid carcinoma , 2022 .